Moderna, an American biotech company, expects to start their largest study yet of its Covid-19 vaccine candidate on July 27, according to details released Tuesday on a government database that tracks clinical trials conducted around the world.
Here is how the vaccine trial will work:
- For the phase three study, researchers plan to enroll 30,000 adult participants, including people whose locations or circumstances put them at high-risk of infection.
- One group will be injected with 100 micrograms of the vaccine on day one and again on day 29. A second group will be injected with two doses of a placebo for comparison.
- Fourteen days after the participants get their second dose, the researchers will be looking at whether they develop Covid-19.
- The participants will be followed for two years after receiving their second dose.
The study will be conducted at 87 locations across the United States.
Remember: Moderna’s vaccine candidate is one of 23 in clinical trials around the world, according to the World Health Organization.
Moderna's Covid-19 vaccine candidate is expected to be the first in the United States to begin phase three trials.